Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Buy
69
ACAD Quote, Financials, Valuation and Earnings
Last price:
$26.79
Seasonality move
:
9.99%
Day range:
$26.49 - $27.20
52-week range:
$13.40 - $28.35
Dividend yield:
0%
P/E ratio:
17.23x
P/S ratio:
4.31x
P/B ratio:
4.94x
Volume:
756.9K
Avg. volume:
1.4M
1-year change:
52.16%
Market cap:
$4.5B
Revenue:
$957.8M
EPS (TTM):
$1.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$284.8M | $0.13 | 16.55% | 16.61% | $30.74 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$207.8M | $1.63 | 5.42% | 138.16% | $109.25 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$142.7M | $0.59 | 0.87% | 32.59% | $34.86 |
|
FOLD
Amicus Therapeutics, Inc.
|
$162.3M | $0.09 | 20.08% | 234.42% | $14.83 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.5B | $10.56 | 14.99% | 45.22% | $824.69 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$61.8M | -- | 23.5% | -- | $13.63 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$26.78 | $30.74 | $4.5B | 17.23x | $0.00 | 0% | 4.31x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$76.28 | $109.25 | $1.7B | 46.78x | $0.00 | 0% | 1.87x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$22.72 | $34.86 | $2.8B | 13.26x | $0.00 | 0% | 4.99x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.28 | $14.83 | $4.4B | -- | $0.00 | 0% | 7.31x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$796.55 | $824.69 | $83.7B | 19.07x | $0.88 | 0.44% | 6.16x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$7.33 | $13.63 | $433.2M | -- | $0.00 | 0% | 2.03x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.825 | 1.52% | 2.70x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.736 | 30.7% | 2.40x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
0.31% | -0.785 | 0.12% | 6.19x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | -0.094 | 4.57% | 3.19x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$116.4M | $66.3M | 27.37% | 27.48% | 44.66% | $32.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
ACADIA Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ACAD or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 10.59%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About ACAD or ANIP?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $30.74, signalling upside risk potential of 14.78%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 43.22%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is ACAD or ANIP More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.679, which suggesting that the stock is 32.083% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.46%.
-
Which is a Better Dividend Stock ACAD or ANIP?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ACAD or ANIP?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.23x while ANI Pharmaceuticals, Inc.'s PE ratio is 46.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.31x versus 1.87x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.31x 17.23x $278.6M $71.8M ANIPANI Pharmaceuticals, Inc.1.87x 46.78x $227.8M $24.1M
-
Which has Higher Returns ACAD or CPRX?
Catalyst Pharmaceuticals, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 35.57%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M CPRXCatalyst Pharmaceuticals, Inc.78.44% $0.42 $923.1M -
What do Analysts Say About ACAD or CPRX?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $30.74, signalling upside risk potential of 14.78%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.86 which suggests that it could grow by 53.42%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 CPRXCatalyst Pharmaceuticals, Inc.7 0 0 -
Is ACAD or CPRX More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.679, which suggesting that the stock is 32.083% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.786%.
-
Which is a Better Dividend Stock ACAD or CPRX?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or CPRX?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.23x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.31x versus 4.99x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.31x 17.23x $278.6M $71.8M CPRXCatalyst Pharmaceuticals, Inc.4.99x 13.26x $148.4M $52.8M
-
Which has Higher Returns ACAD or FOLD?
Amicus Therapeutics, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 10.24%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About ACAD or FOLD?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $30.74, signalling upside risk potential of 14.78%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.88%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 FOLDAmicus Therapeutics, Inc.2 5 0 -
Is ACAD or FOLD More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.679, which suggesting that the stock is 32.083% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock ACAD or FOLD?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or FOLD?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.23x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.31x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.31x 17.23x $278.6M $71.8M FOLDAmicus Therapeutics, Inc.7.31x -- $169.1M $17.3M
-
Which has Higher Returns ACAD or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 38.89%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About ACAD or REGN?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $30.74, signalling upside risk potential of 14.78%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $824.69 which suggests that it could grow by 3.53%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 REGNRegeneron Pharmaceuticals, Inc.16 8 0 -
Is ACAD or REGN More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.679, which suggesting that the stock is 32.083% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.
-
Which is a Better Dividend Stock ACAD or REGN?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or REGN?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.23x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.31x versus 6.16x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.31x 17.23x $278.6M $71.8M REGNRegeneron Pharmaceuticals, Inc.6.16x 19.07x $3.8B $1.5B
-
Which has Higher Returns ACAD or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of -40.15%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About ACAD or VNDA?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $30.74, signalling upside risk potential of 14.78%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 85.88%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is ACAD or VNDA More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.679, which suggesting that the stock is 32.083% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.
-
Which is a Better Dividend Stock ACAD or VNDA?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or VNDA?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 17.23x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.31x versus 2.03x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.31x 17.23x $278.6M $71.8M VNDAVanda Pharmaceuticals, Inc.2.03x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
